| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10052048 | HBV | ENSG00000008394.13 | protein_coding | MGST1 | No | No | 4257 | P10620 |
| TVIS20050550 | HPV | ENSG00000008394.13 | protein_coding | MGST1 | No | No | 4257 | P10620 |
| TVIS44005502 | HTLV-1 | ENSG00000008394.13 | protein_coding | MGST1 | No | No | 4257 | P10620 |
| TVIS44031862 | HTLV-1 | ENSG00000008394.13 | protein_coding | MGST1 | No | No | 4257 | P10620 |
| TVIS44041028 | HTLV-1 | ENSG00000008394.13 | protein_coding | MGST1 | No | No | 4257 | P10620 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | MGST1 |
|---|---|
| DrugBank ID | DB00143 |
| Drug Name | Glutathione |
| Target ID | BE0002282 |
| UniProt ID | P10620 |
| Regulation Type | |
| PubMed IDs | 17306223; 17297922 |
| Citations | Siritantikorn A, Johansson K, Ahlen K, Rinaldi R, Suthiphongchai T, Wilairat P, Morgenstern R: Protection of cells from oxidative stress by microsomal glutathione transferase 1. Biochem Biophys Res Commun. 2007 Apr 6;355(2):592-6. Epub 2007 Feb 12.@@Busenlehner LS, Alander J, Jegerscohld C, Holm PJ, Bhakat P, Hebert H, Morgenstern R, Armstrong RN: Location of substrate binding sites within the integral membrane protein microsomal glutathione transferase-1. Biochemistry. 2007 Mar 13;46(10):2812-22. Epub 2007 Feb 13. |
| Groups | Approved; Investigational; Nutraceutical |
| Direct Classification | Peptides |
| SMILES | N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O)C(O)=O |
| Pathways | Arachidonic Acid Metabolism; Flurbiprofen Action Pathway; 4-Hydroxybutyric Aciduria/Succinic Semialdehyde Dehydrogenase Deficiency; Oxaprozin Action Pathway; Rofecoxib Action Pathway; Pyruvate Kinase Deficiency; Acetaminophen Metabolism Pathway; Mefenamic Acid Action Pathway; Bromfenac Action Pathway; 5-Oxoprolinuria; gamma-Glutamyltransferase Deficiency; Naproxen Action Pathway; Sulindac Action Pathway; Glutathione Synthetase Deficiency; Piroxicam Action Pathway; Nabumetone Action Pathway; 2-Hydroxyglutric Aciduria (D and L Form); Meloxicam Action Pathway; Cyclophosphamide Action Pathway; Succinic Semialdehyde Dehydrogenase Deficiency; Valdecoxib Action Pathway; Ketorolac Action Pathway; 5-Oxoprolinase Deficiency; Acetylsalicylic Acid Action Pathway; Antipyrine Action Pathway; Glutathione Metabolism; Diclofenac Action Pathway; Homocarnosinosis; Cyclophosphamide Metabolism Pathway; Nepafenac Action Pathway |
| PharmGKB | PA449780 |
| ChEMBL | CHEMBL1543 |
